Compare AJANTA PHARMA with NEULAND LABS - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs NEULAND LABS - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA NEULAND LABS AJANTA PHARMA/
NEULAND LABS
 
P/E (TTM) x 24.0 57.5 41.7% View Chart
P/BV x 6.7 4.4 153.3% View Chart
Dividend Yield % 0.5 0.1 636.4%  

Financials

 AJANTA PHARMA   NEULAND LABS
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-19
NEULAND LABS
Mar-20
AJANTA PHARMA/
NEULAND LABS
5-Yr Chart
Click to enlarge
High Rs1,422754 188.7%   
Low Rs898247 363.0%   
Sales per share (Unadj.) Rs233.5594.5 39.3%  
Earnings per share (Unadj.) Rs44.012.6 348.0%  
Cash flow per share (Unadj.) Rs52.237.0 140.9%  
Dividends per share (Unadj.) Rs9.002.00 450.0%  
Dividend yield (eoy) %0.80.4 194.2%  
Book value per share (Unadj.) Rs255.1553.4 46.1%  
Shares outstanding (eoy) m88.0212.83 686.0%   
Bonus/Rights/Conversions BB--  
Price / Sales ratio x5.00.8 590.0%   
Avg P/E ratio x26.439.6 66.6%  
P/CF ratio (eoy) x22.213.5 164.5%  
Price / Book Value ratio x4.50.9 502.7%  
Dividend payout %20.515.8 129.3%   
Avg Mkt Cap Rs m102,0816,421 1,589.9%   
No. of employees `0006.81.3 530.4%   
Total wages/salary Rs m4,3071,236 348.6%   
Avg. sales/employee Rs Th3,022.65,949.4 50.8%   
Avg. wages/employee Rs Th633.4963.8 65.7%   
Avg. net profit/employee Rs Th569.1126.4 450.1%   
INCOME DATA
Net Sales Rs m20,5547,627 269.5%  
Other income Rs m21139 542.6%   
Total revenues Rs m20,7657,666 270.9%   
Gross profit Rs m5,6641,019 555.9%  
Depreciation Rs m721313 230.4%   
Interest Rs m12216 5.4%   
Profit before tax Rs m5,143529 971.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,273367 346.8%   
Profit after tax Rs m3,870162 2,387.5%  
Gross profit margin %27.613.4 206.3%  
Effective tax rate %24.869.4 35.7%   
Net profit margin %18.82.1 886.0%  
BALANCE SHEET DATA
Current assets Rs m11,8125,152 229.3%   
Current liabilities Rs m3,7763,576 105.6%   
Net working cap to sales %39.120.7 189.3%  
Current ratio x3.11.4 217.1%  
Inventory Days Days77105 73.6%  
Debtors Days Days8291 89.8%  
Net fixed assets Rs m14,3983,969 362.8%   
Share capital Rs m175129 136.0%   
"Free" reserves Rs m22,2776,971 319.6%   
Net worth Rs m22,4527,100 316.2%   
Long term debt Rs m7774 0.9%   
Total assets Rs m26,96212,310 219.0%  
Interest coverage x444.33.5 12,867.9%   
Debt to equity ratio x00.1 0.3%  
Sales to assets ratio x0.80.6 123.0%   
Return on assets %14.43.1 469.0%  
Return on equity %17.22.3 755.0%  
Return on capital %23.09.5 242.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m10,6825,187 205.9%   
Fx outflow Rs m2,1021,593 132.0%   
Net fx Rs m8,5803,594 238.7%   
CASH FLOW
From Operations Rs m3,748573 653.6%  
From Investments Rs m-2,228-487 457.7%  
From Financial Activity Rs m-1,475-55 2,690.9%  
Net Cashflow Rs m4533 138.7%  

Share Holding

Indian Promoters % 73.8 36.3 203.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.6 63.7 2.4%  
FIIs % 7.6 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 63.7 26.7%  
Shareholders   20,968 12,705 165.0%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   IPCA LABS  SANOFI INDIA  ALEMBIC PHARMA  PROCTER & GAMBLE HEALTH  NOVARTIS  

Compare AJANTA PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty Recover From Day's Low to End Strong; TCS & Wipro Rally Over 3.5%(Closing)

Indian share markets recouped early losses during closing hours and ended today's volatile session higher, helped by gains in metals and banking stocks.

Related Views on News

AJANTA PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 64.2% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 64.2% YoY). Sales on the other hand came in at Rs 7 bn (up 15.0% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

NEULAND LABS Announces Quarterly Results (3QFY21); Net Profit Up 141.5% (Quarterly Result Update)

Feb 3, 2021 | Updated on Feb 3, 2021

For the quarter ended December 2020, NEULAND LABS has posted a net profit of Rs 267 m (up 141.5% YoY). Sales on the other hand came in at Rs 2 bn (up 20.5% YoY). Read on for a complete analysis of NEULAND LABS's quarterly results.

AJANTA PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 46.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 46.3% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

NEULAND LABS 2019-20 Annual Report Analysis (Annual Result Update)

Sep 2, 2020 | Updated on Sep 2, 2020

Here's an analysis of the annual report of NEULAND LABS for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of NEULAND LABS. Also includes updates on the valuation of NEULAND LABS.

AJANTA PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 28.9% (Quarterly Result Update)

Aug 24, 2020 | Updated on Aug 24, 2020

For the quarter ended June 2020, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 7 bn (up 9.2% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave(Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

An India Revival Stock I'm Bullish On...(Profit Hunter)

Apr 9, 2021

This could take India to the position of 3rd largest economy.

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

Why the Market Fell Yesterday(Fast Profits Daily)

Apr 6, 2021

In this video, I'll tell you the two reasons why the market fell on Monday and how you can prepare yourself for such events in the future.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Apr 15, 2021 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA - LUPIN COMPARISON

COMPARE AJANTA PHARMA WITH

MARKET STATS